Dr. Michael K. Pickens, D.O.
Pediatric Gastroenterology (Pediatric Gastroenterology Physician)
4800 Sand Point Way Ne
Seattle, WA 98105
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
At a glance
- Medical school
- Oklahoma State University College of Osteopathic Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2007
Licensed in Washington since 2009, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: Oklahoma State University College of Osteopathic Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Gastroenterology Physician primary
WA license OP60086591 (first issued 2009; active) -
Pediatrics Physician
WA license OP60086591 (first issued 2009; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- The Association of Chrmc and University Physicians (311 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 3 companies reported 5 payments worth $10,280 in total to this clinician.
| Regeneron Pharmaceuticals, Inc. | $4,338 |
|---|---|
| Genzyme Corporation | $3,964 |
| Regeneron Healthcare Solutions, Inc. | $1,978 |
| Compensation for services other than consulting (speaking, faculty) | $5,817 |
|---|---|
| Consulting Fee | $4,338 |
| Food and Beverage | $125 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 14, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,839 |
| Regeneron Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $2,892 |
| Regeneron Healthcare Solutions, Inc. Mar 14, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,978 |
| Regeneron Pharmaceuticals, Inc. Nov 7, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,446 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $26,532 in research payments for these studies, mostly to the institutions running them.
- A U.S. Registry of Eosinophilic Esophagitis Pediatric, Adolescent and Adult Patients Treated With DUPIXENT® As Standard of Care
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06693531 - A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT05831176
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.